應(yīng)用Columbus?系統(tǒng)行心房顫動(dòng)射頻導(dǎo)管消融的療效評(píng)價(jià)

打開文本圖片集

[中圖分類號(hào)]R541.75[文獻(xiàn)標(biāo)志碼]A[文章編號(hào)]2097-5716（2025）03-0338-04

DOI： 10.13308/j.issn.2097-5716.2025.03.005

[引用格式］吳健民，夏雨，胡志成，等.應(yīng)用Columbus@系統(tǒng)行心房顫動(dòng)射頻導(dǎo)管消融的療效評(píng)價(jià)[J].實(shí)用心電與臨床診療，2025，34（3）：338-341，357.

Therapeutic effect assessment of radiofrequency catheter ablation for atrial fibrillation by Columbus °ledast system WU Jianmin'， XIAYu2 ，HU Zhicheng2，WU Lingmin2，DING Ligang2，YAO Yan2（1. Department of Cardiology，Shaoxing Second Hospital，，Shaoxing Zhejiang 31200；2.Arrhythmia Center，F(xiàn)uwai Hospital，Chinese Academy of Medical Sciences，Beijing 100037，China）

[Abstract]ObjectiveTo study the clinical efficacy and safetyof radiofrequency catheter ablation for atrial fibrillation （AF）by domestic minimally invasive Columbus@ system.MethodsA total of 26 patients with AF who had undergone radiofrequency catheter ablation with Columbus@ system and itssupporting catheter were successively selected.The immediate success rate of surgery，intraoperative related parameters and surgery-related complications were recorded，while the recurrence of AF and the occurrence of adverse events were observed during follow-up.ResultsThe enrolled 26 patients were allparoxysmal AF.Pulmonaryvein isolation was sucessfully achieved during operation，and there were no complications related to radiofrequency catheter ablation during perioperative period. During a mean follow-up of （ 5.92±1.94 ）months，AF recurred in 5 of 26 patients （19.23% ）.No serious adverse events such as embolism，bleeding，atrial esophageal fistula，or death occurred during the follow-up. ConclusionRadiofrequency catheter ablation for AF by using domestic minimall invasive Columbus@ system is clinically feasible， with satisfactory short-term efficacy and safety.

[Key words] atrial fibrillation；radiofrequency catheter ablation； Columbus@ system； three-dimensional mapping

心房顫動(dòng)（簡(jiǎn)稱房顫）是最常見的持續(xù)性心律失常，會(huì)增加體循環(huán)栓塞和心力衰竭的風(fēng)險(xiǎn)，房顫患者的死亡風(fēng)險(xiǎn)是無房顫患者的 1.5～1.9 倍[1]射頻導(dǎo)管消融作為一種安全、有效的房顫治療方法，藥物難治性癥狀性房顫正是其I類適應(yīng)證[2]目前，射頻消融仍是房顫導(dǎo)管消融的主要能量，臨床上使用較廣泛的兩種心臟電生理三維標(biāo)測(cè)系統(tǒng)分別為美國(guó)強(qiáng)生公司生產(chǎn)的Carto系統(tǒng)和Abbott公司研發(fā)的Ensite系統(tǒng)，均為美國(guó)進(jìn)口。（剩余5424字）